Dr. Nir Barzilai is a chaired Professor of Medicine and Genetics and Director of the Nathan Shock Center of Excellence in the Biology of Aging, the biggest center in the world to study the biology of aging. He is the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several developed drugs are based, in part, on these paradigm-changing studies.

Dr. Barzilai is leading the TAME (Targeting/Taming Aging with Metformin) multi-center study to prove that the multiple morbidities of aging can be delayed in humans and to change FDA indications to allow for next-generation interventions against aging.

Dr. Barzilai is a founder of CohBar, Inc. (now a public company), and Chief Medical Advisor for Life Biosciences. He is a co-scientific director of the American Federation for Aging Research (AFAR) and on the board of AFAR and CohBar.

Dr. Barzilai is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award.

Dr. Barzilai has been featured in major papers, TV programs, and documentaries (TEDx and TEDMED), and has been consulting or presented the promise for targeting aging at the Singapore Prime Minister Office, several international banks, the Vatican, Pepsico, Milkin Institute, The Economist, and Wired Magazine.